Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9123MR)

This product GTTS-WQ9123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9123MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12788MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ14194MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6233MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ3350MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ9448MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ2708MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ3416MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ14515MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW